Cognitive symptoms improve in migraine with eptinezumab

Adults with migraine whose previous preventive therapy had failed saw improvements in cognitive symptoms with 12 months of eptinezumab, according to a poster presented at the American Headache Society 68th Annual Scientific Meeting. Eptinezumab (Vypeti; Lundbeck) targets calcitonin gene-related peptides (CGRPs) to prevent episodic and chronic migraine, according to Richard B. Lipton, MD, Edwin S.